Abstract

Mitochondrial dysfunction and mutations in mitochondrial DNA have been frequently reported in cancer cells. Mitochondrial gene-expression signatures of transformed cells have been identified; however, the phenotypic effects of these genetic alterations remain to be established. Identification of mitochondrial proteins that are aberrantly expressed in cancer cells has been made possible by the recent development of mitochondrial functional proteomics and could identify new markers for early detection and risk assessment, as well as targets for therapeutic intervention.

Author affiliations

1. Mukesh Verma, Jacob Kagan and Sudhir Srivastava are at the Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA.
2. David Sidransky is at Johns Hopkins University, Department of Otolaryngology: Head/Neck Surgery, 818 Ross Research Building, 720 Rutland Avenue, Baltimore, Maryland 21205-2196, USA.

Correspondence to: Sudhir Srivastava¹ Email: ss1a@nih.gov